Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers

Background: Programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitor is one of the most popular immune therapies. Biomarkers for predicting response are highly needed, but no biomarkers are widely used till now. Patients and methods: From February 2018 to April 2019, pan-cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yilin, Lin, Shuchen, Zhang, Ping, Zhang, Jian, Ji, Dongmei, Tao, Zhonghua, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846968/
https://www.ncbi.nlm.nih.gov/pubmed/33440424
http://dx.doi.org/10.1042/BSR20202613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846968/
https://www.ncbi.nlm.nih.gov/pubmed/33440424
http://dx.doi.org/10.1042/BSR20202613

Ejemplares similares